Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients  by Dang, Duyen T. et al.
Decreased expression of the gut-enriched Kru«ppel-like factor gene in
intestinal adenomas of multiple intestinal neoplasia mice and in colonic
adenomas of familial adenomatous polyposis patients
Duyen T. Danga, Kurtis E. Bachmanb, Channing S. Mahatana, Long H. Dangc,
Francis M. Giardielloa;c, Vincent W. Yanga;d;*
aDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
bThe Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
cThe Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
dDivision of Gastroenterology, Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Ross 918, 720 Rutland Avenue,
Baltimore, MD 21205, USA
Received 27 March 2000; received in revised form 5 June 2000
Edited by Ned Mantei
Abstract Gut-enriched Kru«ppel-like factor (GKLF) is a zinc
finger-containing transcription factor, the expression of which is
associated with growth arrest. We compared Gklf expression in
intestinal and colonic adenomas to normal mucosa in multiple
intestinal neoplasia (Min) mice and familial adenomatous
polyposis (FAP) patients, respectively, using semi-quantitative
RT-PCR. In Min mice, the level of Gklf transcript is highest in
normal-appearing intestinal tissues and decreases as the size of
the adenoma increases. In FAP patients, the level of GKLF
transcript is lower in adenomas compared to paired normal-
appearing mucosa from the same patient or normal colonic
mucosa from control individuals without FAP. The possibility of
DNA methylation as a cause for the decreased expression of Gklf
in adenomas of Min mice was investigated by methylation-
specific PCR. Results indicate that the Gklf gene is not
methylated in either normal or tumorous tissues. The findings
of our study are therefore consistent with the potential role of
GKLF as a negative growth regulator of gut epithelial
cells. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The mammalian intestinal epithelium is a rapidly prolifer-
ating system that is highly susceptible to neoplastic transfor-
mations. Approximately 50% of individuals in the Western
populations will develop a colorectal neoplasm by age 70,
and colon cancer is the second leading cause of cancer deaths
in the USA [1,2]. As delineated by Fearon and Vogelstein [3],
colonic tumors arise in a stepwise fashion, evolving from se-
quential mutations in key genes that control growth of epi-
thelial cells. The adenomatous polyposis coli (APC) gene is an
important example, which when mutated predisposes to the
development of colorectal tumors [4^8]. APC functions as a
gatekeeper of colonic epithelial cell proliferation by regulating
the activity of L-catenin and Tcf-4 [9,10]. Mutations in APC
can often be identi¢ed in early neoplastic changes such as
aberrant crypt foci and adenomas [11]. Subsequent mutations
in other genes cause tumor progression. This paradigm is
evident in patients with the autosomal dominant syndrome
familial adenomatous polyposis (FAP), who carry a single
germline mutant allele of the APC gene. These patients devel-
op adenomas when they acquire a somatic mutation of their
wild-type APC allele, per Knudson’s ‘two-hit’ hypothesis
[8,12]. Consequently, FAP patients develop hundreds to thou-
sands of colonic adenomas starting in teenage years with in-
evitable progression to colorectal cancer. A murine model for
FAP, the multiple intestinal neoplasia (Min) mouse, was gen-
erated by N-ethyl-N-nitrosourea mutagenesis [13]. These mice
carry a germline mutation in murine Apc [14]. On a C57BL/6J
genetic background, Min mice develop an average of 50 ad-
enomas per animal throughout their intestinal tract by the
time of their death, usually at 150 days of age [13].
The gut-enriched Kru«ppel-like factor (GKLF; also called
Kru«ppel-like factor 4 or KLF4) is a recently identi¢ed Kru«p-
pel-type transcription factor with three C2H2 zinc ¢ngers
[15,16]. Gklf is highly expressed in the epithelial cells of the
gastrointestinal tract [16^18] and the skin [18,19], as well as in
vascular endothelial cells [20]. Several lines of evidence suggest
that GKLF is important in regulating proliferation and di¡er-
entiation of epithelial cells. During fetal development in mice,
the level of Gklf transcript is low initially, starts to rise on
embryonic day 13 and peaks at embryonic day 17, which
corresponds to a critical period of gut epithelium morphogen-
esis [21]. In vivo, Gklf is primarily expressed in the post-mi-
totic, terminally di¡erentiated epithelial cells of the intestine
[16] and the skin [18,19]. In cultured cells, expression of Gklf
is temporally associated with conditions that promote growth
arrest due to serum deprivation or contact inhibition, and
constitutive production of GKLF results in the inhibition of
DNA synthesis [16]. Lastly, in mice de¢cient in Gklf, late-
stage di¡erentiation of the epidermis is disturbed and they
die shortly after birth due to inability to maintain a skin
barrier [19].
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Our group has been investigating the expression of Gklf
during tumorigenesis. We previously reported that Gklf ex-
pression is decreased in the whole small intestines of Min
mice when compared to controls, starting at 12 weeks of
age [21]. While the level of Gklf transcript in the adenomas
of Min mice was not directly evaluated, this previous study
did suggest that a decreased expression of Gklf might be re-
lated to tumor development. Our current study measures the
levels of Gklf transcripts in the intestinal tumors of Min mice
and in the colonic adenomas of FAP patients compared to
normal-appearing mucosa. The results indicate that levels of
Gklf transcript are similarly decreased in tumors from Min
mice and FAP patients comparing to the normal mucosa.
These studies provide further evidence for the potential in-
volvement of GKLF in regulating proliferation of gut epithe-
lial cells.
2. Materials and methods
2.1. Animals
Wild-type (Apc+/+) and Min (Apc+/3) C57BL/6J mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME). The Min
pedigree was maintained by crossing male Min mice with female
wild-type C57BL/6J mice. The Min mice were identi¢ed by an al-
lele-speci¢c polymerase chain reaction (PCR) as previously described
[22]. All animals were killed at age 5 months by CO2 asphyxiation in
accordance with the animal protocol of the Johns Hopkins University.
From Min mice, small intestine and colon were dissected and adeno-
mas carefully removed under a dissecting microscope and snap-frozen.
The adenomas were pooled according to the following sizes: 6 3 mm,
3^6 mm, and s 6 mm. For controls, segments of intestine without
tumors from Min mice and age-matched wild-type littermates were
also retrieved and snap-frozen in liquid nitrogen.
2.2. Human tissues
Tissue samples from FAP patients were obtained from the Johns
Hopkins Hospital tissue bank. Two sets of paired samples from three
di¡erent patients with FAP were obtained. Each pair consisted of two
standard biopsy specimens of normal-appearing mucosa and two
standard biopsy specimens of an adenoma from each patient obtained
during colonoscopy. Samples had previously been histologically con-
¢rmed as consisting of either normal mucosa or adenomas. Biopsy
samples of the normal colon were also obtained from two individuals
without FAP who underwent diagnostic colonoscopy for other med-
ically indicated reasons.
2.3. Preparation of RNA and genomic DNA
Total RNA and genomic DNA were extracted from tissues using
the TRIzol Reagent protocol from Life Technologies, Inc. (LTI, Gai-
thersburg, MD). Due to a paucity of materials, tumors and non-tu-
mor-bearing sections of the intestines were pooled from three di¡erent
Min mice prior to RNA extraction. Similarly, tissues from wild-type
mice were pooled from three di¡erent animals. After determining the
concentration of the RNA samples by optical density measurement,
their integrity and quantity were veri¢ed with denaturing agarose gel
electrophoresis.
2.4. Reverse transcription (RT) PCR
Semi-quantitative PCR following reverse transcription was used to
assess transcript levels of the various genes in question. 5 Wg of total
RNA was treated with ampli¢cation-grade DNase I per protocol from
LTI (Gaithersburg, MD). 1 Wg of the DNase I-treated RNA was
reverse transcribed in a 80 Wl reaction containing 50 mM Tris^HCl
(pH 8.3), 75 mM KCl, 10 mM dithiothreitol, 3 mM MgCl2, 0.5 mM
each dGTP, dATP, dTTP, and dCTP, 80 U RNase inhibitor, and 100
pmol random primer, pd(N)6. The reaction was heated to 90‡C for
5 min, cooled slowly to 67‡C, and followed by the addition of 200 U
MMLV reverse transcriptase (LTI, Gaithersburg, MD). The reaction
was then incubated at 42‡C for 1 h followed by 95‡C for 5 min.
Each PCR reaction of 50 Wl consisted of cDNA made from 125 ng
of total RNA, 1UREDTaq PCR bu¡er (10 mM Tris^HCl (pH 8.3),
50 mM KCl, 1 mM MgCl2, and 0.1% gelatin), 2.5 U REDTaq DNA
polymerase (Sigma, St. Louis, MO), 200 WM each dGTP, dATP,
dTTP, dCTP and 40 pmol each of the forward and reverse primer.
The primers used in the PCR reaction were designed from the cDNA
sequences of mouse Gklf and human GKLF (GenBank accession num-
bers U20344 and AF105036, respectively). For mouse Gklf, the for-
ward primer is 5P-AGGTCGGACCACCTTGCCTTACACATG-3P,
the reverse primer is 5P-CCTCACCCCAAGCTCACTGATTTAG-
3P, and the expected PCR product is 439 bp. For human GKLF, the
forward primer is 5P-AGGTCGGACCACCTCGCCTTACACATG-
3P, the reverse primer is 5P-AAGGTAAAGAGAATACAAGGTGA-
TCTTTTATGC-3P, and the expected PCR product is 345 bp. Water
blank and RNA samples not reverse transcribed were used as negative
controls.
To ensure equal loading of cDNA samples, concurrent PCR reac-
tions for L-actin were performed. The primers for L-actin were de-
signed from cDNA sequences of mouse and human L-actin (GenBank
accession numbers M12481 and X00351, respectively). For mouse
L-actin, the forward primer is 5P-TATGCCAACACAGTGTT-
GTCTGG-3P, the reverse primer is 5P-TACTCCTGCTTGCTGATC-
CACAT-3P, and the expected PCR product is 206 bp. For human
L-actin, the forward primer is 5P-TACGCCAACACAGTGCTG-
TCTGG-3P, the reverse primer is 5P-TACTCCTGCTTGCTGATC-
CACAT-3P, and the expected PCR product is 205 bp. In addition,
the levels of transcripts for cytokeratin 19 (CK19) in the collected
mouse specimens were measured by RT-PCR as a means to provide
an estimate of the amount of epithelial cells in the tissues. CK19 is
uniformly distributed in the epithelial cells of rodent small intestine
[23]. The primer sequences used to amplify mouse CK19 cDNA were
5P-GGGTTCAGTACGCATTGGG-3P for the forward primer and 5P-
CTCCACGCTCAGACGCAAG-3P for the reverse primer, and the
expected PCR product is 471 bp [24].
The number of ampli¢cation cycles in the semi-quantitative PCR
was determined from the linear portion of the PCR cycle when am-
pli¢cation was performed with increasing numbers of cycles for Gklf,
L-actin and CK19. Fig. 1 shows the standard curves for Gklf and
L-actin, using cDNA from the distal small intestine of wild-type
mice. For humans, cDNA product from normal-appearing colonic
mucosa was used to generate a standard curve (data not shown).
Each PCR reaction was started at 94‡C for 5 min followed by the
predetermined number of cycles, and terminated after a ¢nal 72‡C
incubation for 10 min. Each cycle included denaturation at 94‡C for
45 s, primer annealing at 55‡C (mouse Gklf, L-actin, and CK19) or
45‡C (human GKLF and L-actin) for 1 min, and extension at 72‡C for
1.5 min. All PCR products were visualized on a 1.5% agarose gel
stained with ethidium bromide.
2.5. Methylation-speci¢c PCR (MSP)
MSP was performed on genomic DNA obtained from mouse tissues
using 1 Wg of DNA modi¢ed with bisul¢te as previously described
[25]. For unmethylated Gklf, the forward primer is 5P-AGTTTTT-
TATTTAGTAATTTGTTTGTGATTTGT-3P and the reverse primer
is 5P-AACACAAAAACTATAATCCAAACAATAAACA-3P, which
were designed to amplify the 172 bp sequence between nucleotides
+107 and +279 of the 5P-untranslated region (UTR) of the mouse
Gklf gene [26]. For methylated Gklf, the forward primer is 5P-TTATT-
TAGTAATTCGTTCGTGATTCGC-3P and the reverse primer is 5P-
CGAAAACTATAATCCGAACGATAAACG-3P, which were de-
signed to amplify the 162 bp sequence between nucleotides +113
and +275 of the 5P UTR of the mouse Gklf gene [26]. The negative
control was a water blank. The positive control for methylation-spe-
ci¢c reaction was in vitro methylated DNA (IVD) from wild-type
mouse, generated by treatment with Sss1 methylase per protocol
from New England Biolabs (Beverly, MA). This treatment renders
all cytosine residues in a CpG dinucleotide methylated. Each PCR
reaction of 50 Wl consisted of 40 ng DNA, 1Ubu¡er as described
[25], 1.25 mM each dGTP, dATP, dTTP, dCTP and 200 ng each
forward and reverse primer. Each PCR reaction was hot-started at
94‡C for 5 min followed by the addition of 2.5 U REDTaq DNA
polymerase (Sigma, St. Louis, MO), and then denatured at 95‡C for
30 s, annealed at 57‡C for 30 s, and extended at 72‡C for 30 s, for a
total of 35 cycles. PCR products were visualized on a 6% non-dena-
turing polyacrylamide gel stained with ethidium bromide.
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3. Results
Fig. 1 shows the optimization of PCR cycle numbers for the
mouse Gklf and L-actin cDNA (panels A and B, respectively),
reversed transcribed from RNA isolated from the small intes-
tine of wild-type mice. The optimal numbers of cycles for the
two genes were selected from the linear region of the curves
(Fig. 1, arrows). Similar optimization was performed on hu-
man GKLF and L-actin, and mouse CK19 genes (results not
shown).
Using the optimized cycle numbers, RT-PCR on RNA ob-
tained from either the normal-appearing portion of the small
intestine or size-selected, pooled intestinal adenomas from
Min mice was performed and compared to RNA from the
intestines of age-matched control littermates. As seen in Fig.
2, the level of Gklf transcript in the normal-appearing portion
of the Min mouse intestine (Fig. 2, lane 2) is slightly lower
than that of the wild-type mice (Fig. 2, lane 1). Importantly,
Fig. 2 shows that the level of Gklf transcript is progressively
decreased in RNA isolated from the adenomas of the Min
mouse intestine and that this decrease is size-dependent (lanes
3^5). The transcript is barely detectable in the group of ad-
enomas that are greater than 6 mm (lane 5). A similar ¢nding
was obtained with a second set of independently isolated tis-
sues (data not shown). The loading of the samples was rea-
sonably equal as judged by the similar transcript amounts for
L-actin (Fig. 2). Moreover, the amounts of epithelial cells in
the various tissues studied were also relatively equal as judged
by the levels of CK19 transcript (Fig. 2).
Next, the level of GKLF transcript in colonic adenomas was
measured and compared to the neighboring, normal-appear-
ing colonic mucosa obtained from three FAP patients and to
biopsied normal colonic specimens from two control individ-
uals. As shown in Fig. 3, in each of the three pairs of speci-
Fig. 1. Optimization of RT-PCR reactions for Gklf and L-actin. cDNA derived from 125 ng total RNA from wild-type mouse intestine was
ampli¢ed for 21^39 cycles using primers for Gklf (A) and 17^35 cycles using primers for L-actin (B). The intensity of the RT-PCR bands, as
measured by quantitative densitometric tracings, as a function of the number of cycles is plotted. The arrows indicate the numbers of cycles se-
lected for subsequent experiments for Gklf and L-actin, respectively.
Fig. 2. Semi-quantitative RT-PCR of Gklf, L-actin and CK19 tran-
scripts in Min and wild-type mouse intestines. RNA was extracted
from the intestines of wild-type mice (WT) and the normal-appear-
ing mucosa of Min mice (0), as well as the pooled adenomas of
Min mouse intestines based on size: 6 3 mm, 3^6 mm, and s 6
mm. cDNA produced from 125 ng total RNA was subject to PCR
using primers for Gklf, L-actin and CK19. Products were resolved
on a 1.5% agarose gel.
Fig. 3. Semi-quantitative RT-PCR of GKLF and L-actin transcripts
in control individuals and FAP patients. RNA was extracted from
biopsied specimens of normal colon from two control individuals
(left panel) and normal-appearing colonic mucosa (N) and adenom-
atous polyps (P) from three FAP patients (right panel). cDNA tem-
plate made from 125 ng total RNA was subject to PCR using prim-
ers for human GKLF. To ensure even loading, the same amount of
template was subjected to PCR using primers for L-actin.
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mens, the level of the GKLF transcript in the adenoma (P)
was lower than that of the paired normal colon (N). Quanti-
tative densitometric tracings of the band intensities for GKLF,
after normalizing to the L-actin levels, revealed a 25^40%
reduction in the GKLF transcript level in the adenomas com-
pared to paired normal-appearing mucosa.
As an initial attempt to understand the mechanism respon-
sible for the decreased expression of Gklf in the tumorous
tissues, MSP on genomic DNA obtained from wild-type or
Min mice was performed. The rationale to address this possi-
bility ¢rst is that the promoter and 5P-UTR of the mouse Gklf
gene contains a large CpG island [26]. Aberrant methylation
of 5P CpG islands has been correlated with the silencing of
gene expression, especially during tumorigenesis [27]. How-
ever, as seen in Fig. 4, in contrast to the positive result ob-
tained from the IVD, no evidence of methylation of the 5P-
UTR of Gklf was found in either the tumorous or non-tumor-
ous tissues, including the liver, an organ that does not express
Gklf. This result suggests that methylation is not involved in
the tissue-speci¢c or tumor-related regulation of expression of
Gklf.
4. Discussion
This study represents a continuing interest of our group in
understanding the relationship between Gklf expression and
intestinal tumorigenesis. Our prior work suggests that GKLF
is a negative regulator of cell growth [16]. We previously
showed that the level of Gklf transcript is decreased in the
whole intestine of Min mice compared to wild-type controls
during the period of tumor formation [21]. The current study
extends this observation by demonstrating that expression of
Gklf and GKLF is selectively decreased in the intestinal ad-
enomas of Min mice and FAP patients, respectively. Whether
decreased expression initiates tumorigenesis or is a result of
tumor progression is unclear. However, the observation that
Gklf transcript level is slightly decreased in normal-appearing
intestine of Min mice compared to control mice suggests a
potential role for GKLF in the early stage of tumorigenesis.
The mechanism for the decreased expression of Gklf in
tumors is presently unknown. Our data show that aberrant
methylation in the 5P-UTR of Gklf as de¢ned by MSP is not
responsible for the decreased expression of Gklf in tumor
tissues from Min mice. Several recent studies suggest that
there may be an alternative explanation. Adenomas of Min
mice and FAP patients arise from the loss of the wild-type
Apc in addition to the inherited germline mutated Apc [8,10].
APC functions by facilitating L-catenin degradation, thus
down-regulating L-catenin translocation into the nucleus and
subsequent binding to Tcf-4 [9,10]. When APC is mutated,
expression of target genes of the L-catenin/Tcf-4 complex in-
cluding those encoding c-Myc, cyclin D1, Tcf-1, and PPAR-N
are aberrantly increased, which leads to accelerated growth
[28^31]. Recently, APC has been shown to induce expression
of Cdx-2, a homeodomain-containing nuclear protein speci¢-
cally expressed in the gut epithelium [32,33]. Similar to
GKLF, Cdx-2 regulates proliferation and di¡erentiation of
the intestinal epithelium [34] and Cdx-2 expression is de-
creased in human and rat adenomas, carcinomas, and colon
cancer cell lines [35,36]. Moreover, 90% of heterozygous Cdx-
2-de¢cient mice develop multiple intestinal adenomatous pol-
yps by 3 months of age [37]. We recently reported that a Cdx-
2 binding site is present in the Gklf promoter, and that Cdx-2
transactivates a reporter gene linked to 1 kb of the Gklf 5P-
£anking region [26]. These results suggest that GKLF is po-
tentially a downstream target gene of Cdx-2, and hence APC.
Additional experiments are in progress to further delineate
this relationship.
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